Drug Profile

Sodium bicarbonate transdermal - Dyve Biosciences

Alternative Names: DYV-700; DYV-702

Latest Information Update: 10 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dyve Biosciences
Class Alkalinising agents; Antigouts; Sodium compounds
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Gout

Most Recent Events

04 Nov 2022 Dyvs Biosciences plans to file an IND application with the US Food and Drug Administration for phase III in US for Gout (Dyve Biosciences Pipeline, November 2022)
27 Jul 2022 Sodium bicarbonate transdermal is still in phase II trials for Gout in USA (Topical)
01 Jun 2022 Efficacy and safety data from the phase II TARGETS trial in Gout released by Dyve Biosciences

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com